| Literature DB >> 35808610 |
Shahla Khalili1, Nazanin Ghane1, Saied Nouri Khorasani1, Fariba Heydari2, Arjan Atwal3,4, Pooya Davoodi3,4.
Abstract
A coaxial nanofibrous scaffold of poly (ε-caprolactone) and gelatin/cellulose acetate encapsulating anti-inflammatory and antibacterial drugs was co-electrospun for skin tissue regeneration. Indomethacin and ciprofloxacin as model drugs were added to the core and the shell solutions, respectively. The effect of the drugs' presence and crosslinking on the scaffold properties was investigated. TEM images confirmed the core-shell structure of the scaffold. The fiber diameter and the pore size of the scaffold increased after crosslinking. The tensile properties of the scaffold improved after crosslinking. The crosslinked scaffold illustrated a higher rate of swelling, and a lower rate of degradation and drug release compared to the uncrosslinked one. Fitting the release data into the Peppas equation showed that Fickian diffusion was the dominant mechanism of drug release from the scaffolds. The results of biocompatibility evaluations showed no cytotoxicity and suitable adhesion and cell growth on the prepared core-shell structure. The antibacterial activity of the scaffolds was studied against one of the most common pathogens in skin wounds, where the existence of ciprofloxacin could prevent the growth of the Staphylococcus aureus bacteria around the scaffold. The obtained results suggested a new coaxial nanofibrous scaffold as a promising candidate for simultaneous tissue regeneration and controlled drug release.Entities:
Keywords: antibacterial activity; cellulose acetate; core–shell nanofibers; drug release; electrospinning; gelatin; poly (ε-caprolactone)
Year: 2022 PMID: 35808610 PMCID: PMC9269477 DOI: 10.3390/polym14132565
Source DB: PubMed Journal: Polymers (Basel) ISSN: 2073-4360 Impact factor: 4.967
The electrospinning condition, fiber diameter, pore diameter, and surface porosity of prepared scaffolds.
| Sample Code | Shell Flow Rate (mL·h−1) | Core Flow Rate (mL·h−1) | Fiber Diameter (nm) | Pore Diameter (µm) | Surface Porosity (%) |
|---|---|---|---|---|---|
| 1 | 0.5 | 0.2 | 482 ± 401 | 3.0 ± 0.1 | 87 |
| 2 | 0.5 | 0.35 | 752 ± 153 | 4.5 ± 0.2 | 87 |
| 3 | 0.5 | 0.5 | 405 ± 60 | 2.6 ± 0.1 | 88 |
| 4 | 0.3 | 0.2 | 472 ± 206 | 2.3 ± 0.1 | 91 |
| 5 | 0.3 | 0.35 | 364 ± 111 | 2.9 ± 0.1 | 89 |
| 6 | 0.3 | 0.5 | 404 ± 77 | 2.8 ± 0.1 | 87 |
Figure 1The morphological and chemical study; (A) the SEM micrographs (scale bar = 5 μm), and the fiber diameter distribution of the prepared samples at different flow rates of the core and shell solutions; (B) the SEM micrograph (scale bar = 5 μm) and fiber diameter distribution of the optimized scaffold after crosslinking; (C) the EDX spectrum of the prepared scaffold; (D) the TEM image of the prepared core–shell nanofiber; (E) the FTIR of the prepared scaffolds before and after crosslinking.
Scheme 1A schematic of the core–shell structure with the respective components involved in the formation the scaffold.
Figure 2The mechanical and physical characterizations; (A) the tensile stress–strain curve; (B) the images of the water contact angle test; (C) the PBS absorption (%); (D) the weight loss (%) of the coaxial scaffolds before and after crosslinking.
The tensile modulus, strength, and elongation at break of the core–shell scaffold before and after crosslinking.
| Property | Tensile Modulus (MPa) | Tensile Strength (MPa) | Elongation at Break (%) | |
|---|---|---|---|---|
| Sample | ||||
|
| 1.85 ± 0.2 | 0.26 ± 0.02 | 36 ± 4 | |
|
| 2.4 ± 0.3 | 0.47 ± 0.04 | 44 ± 1 | |
Figure 3(A) The cumulative release of ciprofloxacin from the scaffolds before and after crosslinking; (B) the MTT results; (C) the SEM micrographs of the scaffolds (scale bar = 20 and 100 μm); (D) the antibacterial activity of the prepared scaffolds.
The correlation coefficient (R2) was obtained from different models fitted to the drug release data.
| Scaffold | Peppas Eq. | Zero-Order Eq. | First-Order Eq. | Higuchi Eq. |
|---|---|---|---|---|
|
| y = 0.6117x0.0746 | y = 0.0095x + 26.989 | y = −0.0001x + 1.8917 | y = 0.2905x + 25.385 |
|
| y = 0.6x0.073 | y = 0.0202x + 34.461 | y = −0.0002x + 1.8717 | y = 0.7114x + 29.845 |
The average diameter (mm) of the inhibition zone around the prepared scaffolds.
| Control | Disc with 75 µg Drug | Disc with 150 µg Drug | Uncrosslinked Scaffold | Crosslinked Scaffold |
|---|---|---|---|---|
| 0 | 29.5 ± 0.03 | 30.3 ± 0.02 | 27.4 ± 0.01 | 27.9 ± 0.01 |